Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 20, 2007 Brian Orelli	Teva's Disappointing Phase 2 Results Teva's lupus drug fails to meet its primary endpoint in its phase 2 trial. Investors, take note.
The Motley Fool June 12, 2009 Brian Orelli	Where Good Drugs Go to Die Human Genome Sciences has the potential to pop if Benlysta's phase 3 trials are a success, but tread lightly, history is not on their side.
Chemistry World March 15, 2011 Sarah Houlton	Benlysta breaks 50 year Lupus drug drought The first new treatment for lupus erythematosus in half a century has been approved by the US Food and Drug Administration
The Motley Fool October 30, 2009 Brian Orelli	Earnings? Yawn. Trial Data? Moving! For Human Genome Sciences investors, the anticipation is frightening.
The Motley Fool August 28, 2009 Brian Orelli	Is There Life After a 714% Return? It doesn't get any less risky for Immunomedics.
The Motley Fool October 5, 2005 Stephen D. Simpson	Lupus Trials Spook Investors Lupus is a high-risk, high-reward indication, and today's disappointing trial results aren't the end of the story for Human Genome Sciences. Aggressive and experienced investors might want to take a look at this one, but this is clearly not a stock for the faint of heart.
Chemistry World November 4, 2009 Phil Taylor	New treatment hope for lupus patients GlaxoSmithKline and Human Genome Sciences' Benlysta (belimumab), works by blocking the production of autoantibodies by plasma B-cells, the immune system's primary antibody-producing cells.
The Motley Fool July 27, 2010 Jim Mueller	3 Stocks to Play Biotech Here are three promising ideas for this exciting area.
The Motley Fool June 6, 2011 Brian Orelli	Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market.
The Motley Fool November 2, 2009 Brian Orelli	Finally Convinced? Benlysta Works! Human Genome Sciences succeeds where others have failed.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool January 3, 2011 Brian Orelli	Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure.
The Motley Fool June 9, 2010 Brian Orelli	The Drug Passed, but the Stock Fell? Regeneron only bats .500.
The Motley Fool October 8, 2010 Brian Orelli	Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size.
The Motley Fool February 26, 2010 Brian Orelli	A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus.
The Motley Fool March 30, 2010 Brian Orelli	Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers.
The Motley Fool January 29, 2010 Brian Orelli	How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.
The Motley Fool March 21, 2011 Brian Orelli	Let's See Some Data, Curis Curis investors seem to have shrugged off the multiple unknowns and embraced the potential for the company's skin cancer drug.
The Motley Fool August 27, 2010 Brian Orelli	Down 35%! This Just Shouldn't Happen Someone's to blame and it isn't ImmunoGen.
The Motley Fool July 14, 2011 Brian Orelli	Good Data, but Lots of Competition Regeneron's sarilumab passes a phase 2b trial.
The Motley Fool November 8, 2010 Brian Orelli	No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective.
The Motley Fool April 14, 2011 Brian Orelli	Human Genome Sciences Will Be Profitable, Eventually With its first drug on the market -- nearly 20 years after the company was founded -- Human Genome Sciences should start to show meaningful revenue this year.
The Motley Fool October 5, 2010 Brian Orelli	You Should Have Seen this FDA Rejection Coming This hepatitis C treatment was marked for failure.
The Motley Fool July 28, 2010 Jordan DiPietro	3 Biotechs on Your Radar Screen It's not easy keeping track of all the drugs coming in and out of the development pipeline, but if you can stay up to date, you often have an advantage
The Motley Fool November 2, 2006 Brian Lawler	Aspreva's Growing Cash Pile The drug developer released its quarterly results yesterday, but investors already know what they'll look like.
The Motley Fool January 30, 2009 Brian Orelli	Mark Your Calendars: The Race Is On! In the last couple of weeks, both Schering-Plough and Vertex Pharmaceuticals have announced that their phase 3 hepatitis C drugs trials have finished enrolling patients.
The Motley Fool March 9, 2010 Brian Orelli	The Opportunity That Wasn't Roche and Biogen Idec are suspending development of ocrelizumab for rheumatoid arthritis because patients are coming down with opportunistic infections.
The Motley Fool July 20, 2009 Brian Orelli	Overnight Triple! Yee-Haw! The joys of owning biotech companies. The latest beneficiary, Human Genome Sciences, is up more than 220% today because Benlysta, their new drug for lupus, works.
The Motley Fool November 12, 2010 Brian Orelli	Benlysta: Not Perfect, but Good Enough Human Genome should get past the FDA advisory panel next week.
The Motley Fool August 11, 2010 Brian Orelli	Dang! This Drug Is Shining Brighter Vertex illuminates telaprevir's additional benefit in treating hepatitis C patients.
The Motley Fool September 30, 2010 Brian Orelli	Bristol-Myers' Delayed Steal ZymoGenetics price tag looks more reasonable.
The Motley Fool December 14, 2007 Brian Orelli	An Overnight Three-Bagger It's not often you see stocks triple in one day, but that's what Rigel Pharmaceuticals did. You might be surprised, however, as to why. Investors, take note.
The Motley Fool May 19, 2010 Brian Orelli	The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd.
The Motley Fool November 14, 2011 Brian Orelli	Biotech Uncertainty = Big Upside Potential Aastrom's phase 2 and phase 3 trials don't match up.
The Motley Fool May 24, 2010 Brian Orelli	ASCO Abstracts -- Pops and Drops! Ever since The American Society of Clinical Oncology began posting abstracts on-line -- and before that when they were sent to attendees -- investors have clamored to get a glimpse at the data. Here's your glimpse.
The Motley Fool December 11, 2009 Brian Orelli	Roche and Biogen's Blockbuster Making Good Progress Roche and Biogen move their potential blockbuster through the clinical trial maze.
The Motley Fool February 28, 2011 Brian Orelli	Look Out for Big Growth From This Drug Regeneron's ultra-orphan drug Arcalyst takes a step forward toward a wider audience.
The Motley Fool November 19, 2010 Brian Orelli	Exelixis: Up 32% With Room to Run It was only a phase 2 trial, after all.
The Motley Fool December 31, 2010 Brian Orelli	CEL-SCI Investors Cheer a Bit Too Loudly Finally, a phase 3 trial for cancer therapy Multikine.
The Motley Fool April 30, 2008 Brian Lawler	A Tale of 2 DNA Drugs More trouble for Genentech's No. 2 product, the systemic lupus treatment Rituxan.
The Motley Fool September 27, 2010 Brian Orelli	Better Buy: Ariad Pharmaceuticals or Corcept Therapeutics? A battle of drugless companies looking for their first hit.
The Motley Fool March 16, 2011 Brian Orelli	Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial.
The Motley Fool May 19, 2010 Brian Orelli	A Potential Blockbuster Bites the Dust. Should You Worry? Despite the gloomy headlines, investors shouldn't be upset that Roche and Biogen Idec have decided to end development of ocrelizumab for rheumatoid arthritis.
The Motley Fool November 17, 2010 Brian Orelli	52 Years Down, 1 Month to Go Lupus treatment Benlysta moves closer to approval.
The Motley Fool March 4, 2011 Brian Orelli	Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors.
The Motley Fool March 31, 2011 Brian Orelli	Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones?
The Motley Fool May 31, 2011 Brian Orelli	5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals.
The Motley Fool September 8, 2010 Brian Orelli	You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win.
The Motley Fool August 10, 2010 Ryan McBride	Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive.
The Motley Fool September 9, 2011 Frank Vinluan	GSK Halts Part of Breast Cancer Trial; Drug Can't Top Herceptin GlaxoSmithKline has halted part of a phase 3 breast cancer clinical study after an independent committee concluded that the GSK drug administered alone is unlikely to work better than a rival cancer drug from Roche.